Fe3O4@Poly-dopamine as T2W MR Nanoprobe for breast cancer detection and as inhibitory Agent in Helicobacter Pylori

Document Type : Research Paper

Authors

1 Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Biophysics Falavarjan Branch, Islamic Azad University, Isfahan, Iran

3 Department of Bacteriology and Virology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Falavarjan Branch, Islamic Azad University, Isfahan, Iran

5 Department of Bacteriology and Virology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.22038/nmj.2025.77014.1872

Abstract

Objective(s): Recently, magnetic nanoparticles coated with different ligands have been utilized in diagnosis, drug delivery, and therapy. This study aimed to synthesize,  characterize, and apply Fe3O4 coated with Poly Dopamine (PDA) as an MR imaging nanoprobe and its application in metronidazole-resistant helicobacter pylori (H.pylori).
Materials and Methods: Fe3O4 nanoparticles were characterized and their cytotoxicity was determined in MCF-7 cell lines. Then, coated and non-coated nanoparticles were injected intravenously into  9 xenograft BALB/C mice, and the signal intensity of the T2-weighted MR was assessed. Iron concentrations were measured by ICP-AES, and histopathological assessment was done on harvested critical organs. Finally, The standard disk diffusion method was also used to identify the H.pylori resistance to metronidazole. The minimum inhibitory concentrations and the minimum bactericidal concentration of uncoated and coated iron oxide nanoparticles were investigated.
Results: The MTT assay showed low cytotoxicity at 512 µg/ml. T2 relaxation times of tumors were lower compared to normal tissues. ICP-AES results indicated that the NPs accumulated mostly in the spleen and liver. The histopathology study demonstrated that the vital organ tissues had less morphologic abnormality and apoptotic changes. The minimum inhibitory and minimum bactericidal concentrations of ION@PDA were 16-64 µg/ml and 16-128 µg/ml, respectively. 
Conclusion: Due to the high permeability of nanoprobes in tumors, less cytotoxicity, and its inhibitory effects on metronidazole-resistant H.pylori, ION@PDA may be used as a nano contrast agent in MR imaging for the detection of MCF-7 cells. 

Keywords

References

1.    Al-Musawi S, Albukhaty S, Al-Karagoly H, Sulaiman GM, Jabir MS, Naderi-Manesh H. Dextran-coated superparamagnetic nanoparticles modified with folate for targeted drug delivery of camptothecin. Adv Nat Sci: Nanosci. 2020;11(4):045009.
2.    Stanković A, Mihailović J, Mirković M, Radović M, Milanović Z, Ognjanović M, Janković D, Antić B, Mijović M, Vranješ-Đurić S, Prijović Ž. Aminosilanized flower-structured superparamagnetic iron oxide nanoparticles coupled to 131I-labeled CC49 antibody for combined radionuclide and hyperthermia therapy of cancer. Int J Pharm. 2020;587:119628. 
3.    Laurencin M, Cam N, Georgelin T, Clément O, Autret G, Siaugue JM, Ménager C. Human erythrocytes covered with magnetic core-shell nanoparticles for multimodal imaging. Adv Healthc Mater. 2013;2(9):1209-1212. 
4.    Albukhaty S, Al-Musawi S, Abdul Mahdi S, Sulaiman GM, Alwahibi MS, Dewir YH, Soliman DA, Rizwana H. Investigation of dextran-coated superparamagnetic nanoparticles for targeted vinblastine controlled release, delivery, apoptosis induction, and gene expression in pancreatic cancer cells. Molecules. 2020;25(20):4721. 
5.    Israel LL, Galstyan A, Holler E, Ljubimova JY. Magnetic iron oxide nanoparticles for imaging, targeting and treatment of primary and metastatic tumors of the brain. J Control Release. 2020;320:45-62. 
6.    Ankamwar B, Lai TC, Huang JH, Liu RS, Hsiao M, Chen CH, Hwu YK. Biocompatibility of Fe3O4 nanoparticles evaluated by in vitro cytotoxicity assays using normal, glia and breast cancer cells. Nanotechnology. 2010;21(7):075102. 
7.    Khaniabadi PM, Shahbazi-Gahrouei D, Jaafar MS, Majid AM, Khaniabadi BM, Shahbazi-Gahrouei S. Magnetic iron oxide nanoparticles as T2 MR imaging contrast agent for detection of breast cancer (MCF-7) cell. Avicenna J Med Biotechnol. 2017;9(4):181. 
8.    Dheyab MA, Aziz AA, Khaniabadi PM, Jameel MS. Potential of a sonochemical approach to generate MRI-PPT theranostic agents for breast cancer. Photodiagnosis Photodyn Ther. 2021;33:102177. 
9.    Deda DK, Cardoso RM, Kawassaki RK, de Oliveira AR, Toma SH, Baptista MS, Araki K. Cytotoxicity of methotrexate conjugated to glycerol phosphate modified superparamagnetic iron oxide nanoparticles. J Nanosci Nanotechnol. 2021;21(3):1451-1461. 
10.    Beigi FH, Jazi SS, Shahbazi-Gahrouei D, Khaniabadi PM, Hafezi H, Monajemi R, Amiri GR. Iron oxide nanoparticles coated with polydopamine as a potential nano-photothermal agent for treatment of melanoma cancer: an in vivo study. Lasers Med Sci, 2022. 37(9):3413-3421.    
11.    Palanisamy S, Wang YM. Superparamagnetic iron oxide nanoparticulate system: synthesis, targeting, drug delivery and therapy in cancer. Dalton Trans. 2019;48(26):9490-9515. 
12.    Wang C, Wang Y, Xiao W, Chen X, Li R, Shen Z, Lu F. Carboxylated superparamagnetic Fe3O4 nanoparticles modified with 3-amino propanol and their application in magnetic resonance tumor imaging. BMC Cancer. 2023;23(1):54. 
13.    Liang M, Zhou W, Zhang H, Zheng J, Lin J, An L, Yang S. Tumor microenvironment responsive T 1–T 2 dual-mode contrast agent Fe3O4@ ZIF-8-Zn–Mn NPs for in vivo magnetic resonance imaging. J Mater Chem B. 2023;11(19):4203-4210. 
14.    Liu D, Li J, Wang C, An L, Lin J, Tian Q, Yang S. Ultrasmall Fe@ Fe3O4 nanoparticles as T1–T2 dual-mode MRI contrast agents for targeted tumor imaging. Nanomedicine. 2021;32:102335. 
15.    Liu X, Cao J, Li H, Li J, Jin Q, Ren K, Ji J. Mussel-inspired polydopamine: a biocompatible and ultrastable coating for nanoparticles in vivo. ACS Nano. 2013;7(10):9384-9395. 
16.    Gu X, Zhang Y, Sun H, Song X, Fu C, Dong P. Mussel‐Inspired Polydopamine Coated Iron Oxide Nanoparticles for Biomedical Application. J Nanomater. 2015;2015(1):154592. 
17.    Liao N, Wu M, Pan F, Lin J, Li Z, Zhang D, Wang Y, Zheng Y, Peng J, Liu X, Liu J. Poly (dopamine) coated superparamagnetic iron oxide nanocluster for noninvasive labeling, tracking and targeted delivery of adipose tissue-derived stem cells. Sci Rep. 2016;6(1):18746. 
18.    Zhang T, Li Y, Hong W, Chen Z, Peng P, Yuan S, Qu J, Xiao M, Xu L. Glucose oxidase and polydopamine functionalized iron oxide nanoparticles: Combination of the photothermal effect and reactive oxygen species generation for dual-modality selective cancer therapy. J Mater Chem B. 2019;7(13):2190-2200. 
19.    Li S, Cao M, Song L, Qi P, Chen C, Wang X, Li N, Peng J, Wu D, Hu G, Zhao J. The contribution of toll-like receptor 2 on Helicobacter pylori activation of the nuclear factor-kappa B signaling pathway in gastric epithelial cells. Microb Pathog. 2016;98:63-68. 
20.    Poonyam P, Chotivitayatarakorn P, Vilaichone RK. High effective of 14-day high-dose PPI-bismuth-containing quadruple therapy with probiotics supplement for Helicobacter pylori eradication: a double blinded-randomized placebo-controlled study. Asian Pac J Cancer Prev. 2019;20(9):2859.
21.    Cai Y, Wang C, Chen Z, Xu Z, Li H, Li W, Sun Y. Transporters HP0939, HP0497, and HP0471 participate in intrinsic multidrug resistance and biofilm formation in Helicobacter pylori by enhancing drug efflux. Helicobacter. 2020;25(4):e12715.
22.    Hussein RA, Al-Ouqaili MT, Majeed YH. Detection of clarithromycin resistance and 23SrRNA point mutations in clinical isolates of Helicobacter pylori isolates: Phenotypic and molecular methods. Saudi J Biol Sci. 2022;29(1):513-520. 
23.    Fatahian S, Shahbazi D, Pouladian M, Yousefi MH, Amiri GhR SZ, Jahanbakhsh H. Preparation and magnetic properties investigation of Fe3O4 nanoparticles 99mTc labeled and Fe3O4 nanoparticles DMSA coated. Dig J Nanomater Bios. 2011;6(3):1161-1165.
24.    Beigi, F.H., et al., Assessment of ploy dopamine coated Fe3O4 nanoparticles for melanoma (B16-F10 and A-375) cells detection. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 2020. 20(16): 1918-1926.
25.    Bahjat HH, Ismail RA, Sulaiman GM. Photodetection properties of populated Fe3O4@ TiO2 core–shell/Si heterojunction prepared by laser ablation in water. Appl Phys A. 2022;128(1):8. 
26.    Ahmadian S, Barar J, Saei AA, Fakhree MA, Omidi Y. Cellular toxicity of nanogenomedicine in MCF-7 cell line: MTT assay. J Vis Exp. 2009(26):e1191.
27.    Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. The 1996 guide for the care and use of laboratory animals. Ilar j, 1997; 38(1): 41-48.
28.    Shahbazi‐Gahrouei D, Abdi N, Shahbazi‐Gahrouei S, Hejazi SH, Salehnia Z. In vivo study of anti‐epidermal growth factor receptor antibody‐based iron oxide nanoparticles (anti‐EGFR‐SPIONs) as a novel MR imaging contrast agent for lung cancer (LLC1) cells detection. IET nanobiotechnology. 2020;14(5):369-374. 
29.    Mirzaei N, Poursina F, Faghri J, Talebi M, Khataminezhad MR, Hasanzadeh A, Safaei HG. Prevalence of resistance of Helicobacter pylori strains to selected antibiotics in Isfahan, Iran. Jundishapur J Microbiol. 2013;6(5). 
30.    Hussein RA, Al-Ouqaili MT, Majeed YH. Association between alcohol consumption, cigarette smoking, and Helicobacter pylori infection in Iraqi patients submitted to gastrointestinal endoscopy. J Emerg Med Trauma Acute Care. 2022;2022(6):12. 
31.    Rezaei S, Abadi AT, Mobarez AM. Metronidazole-resistant Helicobacter pylori isolates without rdxA mutations obtained from Iranian dyspeptic patients. New Microb New Infec. 2020;34:100636. 
32.    Hossein-Beigi F, Fatahian S, Shahbazi-Gahrouei D. In-vitro toxicity assessment of polydopamine-coated and uncoated Fe3O4 nanoparticles in cell line B16-F10 (Melanoma Cell).  J Isfahan Med Sch. 2019;37(533):762-767.
33.    Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008 Aug 4;5(4):505-515. 
34.    Eivazi M, Khaniabadi PM, Hejazi SH, Shahbazi-Gahrouei D. Porphyrin–iron oxide nanoparticle functionalized with trastuzumab (ION–PP–TZ) potential MR imaging probe for breast cancer cells. Appl Phys A. 2022;128(6):509. 
35.    Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng. 2005;100(1):1-1. 
36.    Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science. 2006;311(5761):622-627. 
37.    Frantellizzi V, Conte M, Pontico M, Pani A, Pani R, De Vincentis G. New frontiers in molecular imaging with superparamagnetic iron oxide nanoparticles (SPIONs): efficacy, toxicity, and future applications. Nucl Med Mol Imaging. 2020;54:65-80. 
38.    Mustafa TA, Mohammed-Rasheed MA. Accumulation and cytotoxicity assessment of TAT-IONPs on cancerous mammalian cells. Anim Biotechnol. 2021;32(1):100-105. 
39.    Voss L, Hoché E, Stock V, Böhmert L, Braeuning A, Thünemann AF, Sieg H. Intestinal and hepatic effects of iron oxide nanoparticles. Arch Toxicol, 2021. 95(3): 895-905.
40.    Miri A, Najafzadeh H, Darroudi M, Miri MJ, Kouhbanani MA, Sarani M. Iron oxide nanoparticles: biosynthesis, magnetic behavior, cytotoxic effect. ChemistryOpen. 2021;10(3):327-333.
41.    Jeon M, Halbert MV, Stephen ZR, Zhang M. Iron oxide nanoparticles as T1 contrast agents for magnetic resonance imaging: fundamentals, challenges, applications, and prospectives. Adv Mater. 2021;33(23): e1906539.
42.    Unfried K, Albrecht C, Klotz LO, Von Mikecz A, Grether-Beck S, Schins RP. Cellular responses to nanoparticles: target structures and mechanisms. Nanotoxicol. 2007;1(1):52-71.
43.    Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. Nano Sci Technol J. 2010: 278.
44.    Park JH, Von Maltzahn G, Zhang L, Schwartz MP, Ruoslahti E, Bhatia SN, Sailor MJ. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv Mater. 2008;20(9):1630-1635. 
45.    Gupta AK, Naregalkar RR, Vaidya VD, Gupta M. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. Nanomed. 2007;2(1):23-39. 
46.    Al-Ouqaili MT. Depending on HPLC and PCR, detection of aflatoxin B1 extracted from Aspergillus flavus strains and it’ s cytotoxic effect on AFB treated-hematopoietic stem cells obtained from human umbilical cord. Asian J Pharm. 2018;12(3). 
47.    Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pylori isolated from Korean patients.  Int J Antimicrob Agents. 2006;28(1):6-13.
48.    Kato S, Fujimura S, Udagawa H, Shimizu T, Maisawa S, Ozawa K, Iinuma K. Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol. 2002;40(2):649-653.
 
Nanomedicine Journal
Volume 12, Issue 2
April 2025
Pages 202-215

Files

Share

How to cite

Statistics